David Weinstock has served as interim Chief Financial Officer since June 28, 2022, and as Vice President and Chief Accounting Officer since 2009.
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds despite setbacks.
